PM
IMNM icon

Prosight Management’s Immunome IMNM Stock Holding History

Prosight Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,618
Closed -$159K – 44
2025
Q1 		$159K Sell
23,618
-30,724
-57% -$295K 0.05% 38
2024
Q4 		$577K Buy
54,342
+15,207
+39% +$184K 0.16% 35
2024
Q3 		$572K Sell
39,135
-25,865
-40% -$368K 0.14% 42
2024
Q2 		$787K Buy
+65,000
New +$1.02M 0.24% 42

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Prosight Management's IMNM Position: Q2 2025 in Review

Prosight Management sold out of Immunome (IMNM) in Q2 2025, closing a stake of 23,618 shares — an estimated $159K sold.

Prosight Management first reported a position in IMNM in Q2 2024 and held it in 4 quarters. The position peaked at $787K in Q2 2024. 142 funds tracked by Wall St. Rank hold IMNM as of Q2 2025.

  • Prosight Management reported no remaining Immunome position as of Q2 2025 after selling out during the quarter.
  • Prosight Management sold 23,618 Immunome shares in Q2 2025, an estimated $159K.
  • Prosight Management first reported a position in Immunome in Q2 2024 and held it in 4 quarters.
  • Prosight Management's Immunome position peaked at $787K in Q2 2024.
  • 142 funds tracked by Wall St. Rank held Immunome as of Q2 2025.

Based on Prosight Management's 13F filing for Q2 2025, filed 14 Aug 2025.